# Immunocore reports first quarter financial results and provides a business update
Canonical URL: https://biopharmsignal.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update
Ticker: IMCR
Company: Immunocore Holdings plc
Source: Immunocore Holdings plc
Published: 2026-05-06 11:00 EST
Original Source URL: https://www.immunocore.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-31 12:00 EST — [Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma](https://biopharmsignal.com/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma) — Source: Immunocore Holdings plc
- 2026-05-06 11:00 EST — [Immunocore reports first quarter financial results and provides a business update](https://biopharmsignal.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update) — Source: Immunocore Holdings plc
- 2026-04-19 22:00 EST — [KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma](https://biopharmsignal.com/news/IMCR/kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma) — Source: Immunocore Holdings plc
- 2026-04-06 11:00 EST — [Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/IMCR/immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Immunocore Holdings plc
- 2026-03-17 20:30 EST — [Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting](https://biopharmsignal.com/news/IMCR/immunocore-will-present-five-year-overall-survival-data-for-kimmtrak-during-oral-presentation-at-the-2026-aacr-meeting) — Source: Immunocore Holdings plc
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)